Chikungunya Vaccines in Development

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2015 Nov 12

PMID 26554522

Citations 26

Authors

Michael Schwameis

Nina Buchtele

Patricia Pia Wadowski

Christian Schoergenhofer

Bernd Jilma

Affiliations

Soon will be listed here.

Abstract

Chikungunya virus has become a global health threat, spreading to the industrial world of Europe and the Americas; no treatment or prophylactic vaccine is available. Since the late 1960s much effort has been put into the development of a vaccine, and several heterogeneous strategies have already been explored. Only two candidates have recently qualified to enter clinical phase II trials, a chikungunya virus-like particle-based vaccine and a recombinant live attenuated measles virus-vectored vaccine. This review focuses on the current status of vaccine development against chikungunya virus in humans and discusses the diversity of immunization strategies, results of recent human trials and promising vaccine candidates.

Citing Articles

Assessment of heat-killed expressing Chikungunya virus E2 protein as a candidate vaccine for dual protection against Chikungunya virus and .

Patra S, Gajbhiye V, Karpe Y Front Immunol. 2025; 15():1500622.

PMID: 39840038 PMC: 11746998. DOI: 10.3389/fimmu.2024.1500622.

A safe insect-based chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques.

Adam A, Woolsey C, Lu H, Plante K, Wallace S, Rodriguez L NPJ Vaccines. 2024; 9(1):251.

PMID: 39702442 PMC: 11659317. DOI: 10.1038/s41541-024-01047-z.

Pathogenicity and virulence of chikungunya virus.

Freppel W, Silva L, Stapleford K, Herrero L Virulence. 2024; 15(1):2396484.

PMID: 39193780 PMC: 11370967. DOI: 10.1080/21505594.2024.2396484.

Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses.

Pushko P, Lukashevich I, Johnson D, Tretyakova I Viruses. 2024; 16(3).

PMID: 38543793 PMC: 10974764. DOI: 10.3390/v16030428.

IgM-specific linear epitopes on the E2 protein for serodiagnosis of Chikungunya.

Li Q, Dai J, Shi Y, Deng Q, Liao C, Huang J Virus Res. 2023; 339:199292.

PMID: 38042373 PMC: 10714233. DOI: 10.1016/j.virusres.2023.199292.

References

Chretien J, Anyamba A, Bedno S, Breiman R, Sang R, Sergon K . Drought-associated chikungunya emergence along coastal East Africa. Am J Trop Med Hyg. 2007; 76(3):405-7. View

Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak R, Thomas S . Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis. 2015; 15(5):519-27. DOI: 10.1016/S1473-3099(15)70043-5. View

Billeter M, Naim H, Udem S . Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr Top Microbiol Immunol. 2009; 329:129-62. PMC: 7120638. DOI: 10.1007/978-3-540-70523-9_7. View

Uchime O, Fields W, Kielian M . The role of E3 in pH protection during alphavirus assembly and exit. J Virol. 2013; 87(18):10255-62. PMC: 3754015. DOI: 10.1128/JVI.01507-13. View

Pierro A, Rossini G, Gaibani P, Finarelli A, Moro M, Landini M . Persistence of anti-chikungunya virus-specific antibodies in a cohort of patients followed from the acute phase of infection after the 2007 outbreak in Italy. New Microbes New Infect. 2015; 7:23-5. PMC: 4475829. DOI: 10.1016/j.nmni.2015.04.002. View

HARRISON V, Binn L, Randall R . Comparative immunogenicities of chikungunya vaccines prepared in avian and mammalian tissues. Am J Trop Med Hyg. 1967; 16(6):786-91. View

Brandler S, Ruffie C, Combredet C, Brault J, Najburg V, Prevost M . A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine. 2013; 31(36):3718-25. DOI: 10.1016/j.vaccine.2013.05.086. View

Pal P, Fox J, Hawman D, Huang Y, Messaoudi I, Kreklywich C . Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol. 2014; 88(15):8213-26. PMC: 4135940. DOI: 10.1128/JVI.01032-14. View

Fros J, Liu W, Prow N, Geertsema C, Ligtenberg M, Vanlandingham D . Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling. J Virol. 2010; 84(20):10877-87. PMC: 2950581. DOI: 10.1128/JVI.00949-10. View

10.

Ozden S, Huerre M, Riviere J, Coffey L, Afonso P, Mouly V . Human muscle satellite cells as targets of Chikungunya virus infection. PLoS One. 2007; 2(6):e527. PMC: 1885285. DOI: 10.1371/journal.pone.0000527. View

11.

Seyler T, Hutin Y, Ramanchandran V, Ramakrishnan R, Manickam P, Murhekar M . Estimating the burden of disease and the economic cost attributable to chikungunya, Andhra Pradesh, India, 2005-2006. Trans R Soc Trop Med Hyg. 2009; 104(2):133-8. DOI: 10.1016/j.trstmh.2009.07.014. View

12.

Sudeep A, Parashar D . Chikungunya: an overview. J Biosci. 2009; 33(4):443-9. DOI: 10.1007/s12038-008-0063-2. View

13.

Mallilankaraman K, Shedlock D, Bao H, Kawalekar O, Fagone P, Ramanathan A . A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis. 2011; 5(1):e928. PMC: 3019110. DOI: 10.1371/journal.pntd.0000928. View

14.

Wagner J, Pajerowski J, Daniels C, McHugh P, Flynn J, Balliet J . Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line. PLoS One. 2014; 9(4):e94401. PMC: 3979839. DOI: 10.1371/journal.pone.0094401. View

15.

Brandler S, Ruffie C, Najburg V, Frenkiel M, Bedouelle H, Despres P . Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine. 2010; 28(41):6730-9. DOI: 10.1016/j.vaccine.2010.07.073. View

16.

Schilte C, Couderc T, Chretien F, Sourisseau M, Gangneux N, Guivel-Benhassine F . Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. J Exp Med. 2010; 207(2):429-42. PMC: 2822618. DOI: 10.1084/jem.20090851. View

17.

Hallengard D, Lum F, Kummerer B, Lulla A, Lulla V, Garcia-Arriaza J . Prime-boost immunization strategies against Chikungunya virus. J Virol. 2014; 88(22):13333-43. PMC: 4249109. DOI: 10.1128/JVI.01926-14. View

18.

Rager-Zisman B, Bazarsky E, Skibin A, Chamney S, Belmaker I, Shai I . The effect of measles-mumps-rubella (MMR) immunization on the immune responses of previously immunized primary school children. Vaccine. 2003; 21(19-20):2580-8. DOI: 10.1016/s0264-410x(03)00053-7. View

19.

Sam I, Loong S, Michael J, Chua C, Sulaiman W, Vythilingam I . Genotypic and phenotypic characterization of Chikungunya virus of different genotypes from Malaysia. PLoS One. 2012; 7(11):e50476. PMC: 3507689. DOI: 10.1371/journal.pone.0050476. View

20.

Lam S, Chen K, Ng M, Chu J . Expression of plasmid-based shRNA against the E1 and nsP1 genes effectively silenced Chikungunya virus replication. PLoS One. 2012; 7(10):e46396. PMC: 3466284. DOI: 10.1371/journal.pone.0046396. View